Subsequently, we grouped the JMML cases according to the most prevalent molecular subtypes in our cohort of patients (PTPN11, KRAS and NRAS) and compared each group individually with the controls. This evidence concerns the gene PTPN11 and juvenile myelomonocytic leukemia.